Cargando…
Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815558/ https://www.ncbi.nlm.nih.gov/pubmed/33263172 http://dx.doi.org/10.1007/s00702-020-02276-x |
_version_ | 1783638254524825600 |
---|---|
author | Greten, S. Müller-Funogea, J. I. Wegner, F. Höglinger, G. U. Simon, N. Junius-Walker, U. Gerbel, S. Krause, O. Klietz, M. |
author_facet | Greten, S. Müller-Funogea, J. I. Wegner, F. Höglinger, G. U. Simon, N. Junius-Walker, U. Gerbel, S. Krause, O. Klietz, M. |
author_sort | Greten, S. |
collection | PubMed |
description | To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medication appropriateness in PD inpatients applying the FORTA list and drug-drug interaction software, further to assess the adequacy of FORTA list for patients with PD. We retrospectively collected demographic data, comorbidities, laboratory values, and the medication from the discharge letters of 123 geriatric inpatients with PD at the university hospital of Hannover Medical School. Patients suffered on average from 8.2 comorbidities. The majority of the medication was labeled A (60.6% of PD-specific and 40.9% of other medication) or B (22.3% of PD-specific and 26.9% of other medication). Administered drugs labeled with D were amantadine, clozapine, oxazepam, lorazepam, amitriptyline, and clonidine. Overall, 545 interactions were identified, thereof 11.9% severe interactions, and 1.7% contraindicated combinations. 81.3% of patients had at least one moderate or severe interaction. The FORTA list gives rational recommendations for PD-specific and other medication, especially for general practitioners. Considering the demographic characteristics and the common multimorbidity of geriatric PD patients, this study underlines the importance of awareness, education, and preventive interventions to increase drug safety. |
format | Online Article Text |
id | pubmed-7815558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-78155582021-01-25 Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis Greten, S. Müller-Funogea, J. I. Wegner, F. Höglinger, G. U. Simon, N. Junius-Walker, U. Gerbel, S. Krause, O. Klietz, M. J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Original Article To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medication appropriateness in PD inpatients applying the FORTA list and drug-drug interaction software, further to assess the adequacy of FORTA list for patients with PD. We retrospectively collected demographic data, comorbidities, laboratory values, and the medication from the discharge letters of 123 geriatric inpatients with PD at the university hospital of Hannover Medical School. Patients suffered on average from 8.2 comorbidities. The majority of the medication was labeled A (60.6% of PD-specific and 40.9% of other medication) or B (22.3% of PD-specific and 26.9% of other medication). Administered drugs labeled with D were amantadine, clozapine, oxazepam, lorazepam, amitriptyline, and clonidine. Overall, 545 interactions were identified, thereof 11.9% severe interactions, and 1.7% contraindicated combinations. 81.3% of patients had at least one moderate or severe interaction. The FORTA list gives rational recommendations for PD-specific and other medication, especially for general practitioners. Considering the demographic characteristics and the common multimorbidity of geriatric PD patients, this study underlines the importance of awareness, education, and preventive interventions to increase drug safety. Springer Vienna 2020-12-01 2021 /pmc/articles/PMC7815558/ /pubmed/33263172 http://dx.doi.org/10.1007/s00702-020-02276-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Neurology and Preclinical Neurological Studies - Original Article Greten, S. Müller-Funogea, J. I. Wegner, F. Höglinger, G. U. Simon, N. Junius-Walker, U. Gerbel, S. Krause, O. Klietz, M. Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis |
title | Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis |
title_full | Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis |
title_fullStr | Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis |
title_full_unstemmed | Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis |
title_short | Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis |
title_sort | drug safety profiles in geriatric patients with parkinson’s disease using the forta (fit for the aged) classification: results from a mono-centric retrospective analysis |
topic | Neurology and Preclinical Neurological Studies - Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815558/ https://www.ncbi.nlm.nih.gov/pubmed/33263172 http://dx.doi.org/10.1007/s00702-020-02276-x |
work_keys_str_mv | AT gretens drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT mullerfunogeaji drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT wegnerf drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT hoglingergu drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT simonn drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT juniuswalkeru drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT gerbels drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT krauseo drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis AT klietzm drugsafetyprofilesingeriatricpatientswithparkinsonsdiseaseusingthefortafitfortheagedclassificationresultsfromamonocentricretrospectiveanalysis |